Abstract
Background There is insufficient evidence to support clinical decision-making for cancer patients diagnosed with COVID-19 due to the lack of large studies.
Methods We used data from a single large UK Cancer Centre to assess demographic/clinical characteristics of 156 cancer patients with a confirmed COVID-19 diagnosis between 29 February-12 May 2020. Logistic/Cox proportional hazards models were used to identify which demographic and/or clinical characteristics were associated with COVID-19 severity/death.
Results 128 (82%) presented with mild/moderate COVID-19 and 28 (18%) with severe disease. Initial diagnosis of cancer >24m before COVID-19 (OR:1.74 (95%CI: 0.71-4.26)), presenting with fever (6.21 (1.76-21.99)), dyspnoea (2.60 (1.00-6.76)), gastro-intestinal symptoms (7.38 (2.71-20.16)), or higher levels of CRP (9.43 (0.73-121.12)) were linked with greater COVID-19 severity. During median follow-up of 47d, 34 patients had died of COVID-19 (22%). Asian ethnicity (3.73 (1.28-10.91), palliative treatment (5.74 (1.15-28.79), initial diagnosis of cancer >24m before (2.14 (1.04-4.44), dyspnoea (4.94 (1.99-12.25), and increased CRP levels (10.35 (1.0552.21)) were positively associated with COVID-19 death. An inverse association was observed with increased levels of albumin (0.04 (0.01-0.04).
Conclusions A longer-established diagnosis of cancer was associated with increasing severity of infection as well as COVID-19 death, possibly reflecting effects of more advanced malignant disease impact on this infection. Asian ethnicity and palliative treatment were also associated with COVID-19 death in cancer patients.
Contribution to the field In the context of cancer, the COVID-19 pandemic has led to challenging decision-making. These are supported by limited evidence with small case studies being reported from China, Italy, New York and a recent consortium of 900 patients from over 85 hospitals in the USA, Canada, and Spain. As a result of their limited sample sizes, most studies were not able to distinguish between the effects of age, cancer, and other comorbidities on COVID-19 outcomes. Moreover, the case series from New York analysed which patient characteristics are associated with COVID-19 death, but only made a comparison with non-cancer patients. The first results of the COVID-19 and Cancer Consortium provide insights from a large cohort in terms of COVID-19 mortality, though a wide variety of institutions with different COVID-19 testing procedures were included.
Given the current lack of (inter)national guidance for cancer patients in the context of COVID-19, we believe that our large cancer centre can provide an important contribution to the urgent need for further insight into the intersection between COVID-19 and cancer. With comprehensive in-house patient details, consistent inclusion criteria and up-to-date cancer and COVID-19 outcomes, we are in position to provide rapid analytical information to the oncological community.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Data was collected from Guys Cancer Cohort which is a research ethics committee approved research database (Reference number: 18/NW/0297) of all routinely collected clinical data of cancer patients at Guys and St Thomas NHS Foundation Trust (GSTT)
Funding Statement
This project was made possible by funding from the GSTT Cancer Fund
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by the North West-Haydock Research Ethics Committee 18/NW/0297
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email address of co-authors: beth.russell{at}kcl.ac.uk; charlotte.moss{at}kcl.ac.uk; sophie.papa{at}kcl.ac.uk; sheeba.irshad{at}kcl.ac.uk; paul.ross{at}gstt.nhs.uk; james.spicer{at}kcl.ac.uk; shahram.kordasti{at}kcl.ac.uk; Danielle.crawley{at}kcl.ac.uk; harriet.wylie{at}kcl.ac.uk; fidelma.cahill{at}kcl.ac.uk; anna.haire{at}kcl.ac.uk; kamarul.zaki{at}gstt.nhs.uk; fareen.rahman{at}gstt.nhs.uk; ailsa.lumsden{at}gstt.nhs.uk; debra.josephs{at}kcl.ac.uk; mary.lei{at}gstt.nhs.uk; sharmistha.ghosh{at}gstt.nhs.uk; elinor.Sawyer{at}kcl.ac.uk; deborah.enting{at}kcl.ac.uk; angela.swampillai{at}gstt.nhs.uk; claire.harrison{at}gstt.nhs.uk; andrea.dsouza{at}gstt.nhs.uk; simon.gomberg{at}gstt.nhs.uk; paul.fields{at}gstt.nhs.uk; david.wrench{at}gstt.nhs.uk; Kavita.raj{at}gstt.nhs.uk; mary.gleeson{at}gstt.nhs.uk; Kate.Bailey{at}gstt.nhs.uk; Richard.dillon{at}gstt.nhs.uk; matthew.streetly{at}gstt.nhs.uk; anna.rigg{at}gstt.nhs.uk; Richard.sullivan{at}kcl.ac.uk; Saoirse.dolly{at}gstt.nhs.uk; mieke.vanhemelrijck{at}kcl.ac.uk
Data Availability
Data can be requested by contacting charlotte.moss{at}kcl.ac.uk
